Kenneth Lieberman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kenneth Lieberman has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Guillermo Hidalgo
Hackensack Meridian School of Medicine
2 shared publications - Ibrahim Batal
Pathology & Cell Biology, Columbia University Irving Medical Center, New York, USA
2 shared publications - Marlene R. Amoruso
Division of Transplant Surgery Hackensack University Medical Center Hackensack New Jersey USA
2 shared publications - Michael J. Goldstein
Division of Transplantation, Department of Surgery Hackensack Meridian Health Hackensack New Jersey USA
2 shared publications - Namarata G. Jain
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
2 shared publications - Ally Watson
Division of Pediatric Nephrology, Department of Pediatrics Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center Hackensack New Jersey USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1)
Rethinking Proteinuria: Resolution of Donor Derived EXT2‐Associated Membranous Nephropathy Following Renal Transplantation
Exostosin‐2 (EXT2)‐associated membranous nephropathy (MN) represents a subgroup of immune complex‐mediated renal diseases, where transplantation may facilitate clearance of immune deposits. We present a successful kidney transplantation from a 19‐year‐old deceased donor with previously undiagnosed EXT2‐associated MN into a 75‐year‐old male recipient. Despite significant pretransplant donor proteinuria (> 300 mg/dL) and hypoalbuminemia, renal biopsies at procurement demonstrated well‐preserved renal architecture with minimal interstitial fibrosis. Clinical follow‐up showed improvement in recipient renal function, with serum creatinine decreasing from 3.56 mg/dL preoperatively to 0.96 mg/dL (reference range: 0.7–1.3 mg/dL) within 2 months posttransplant. Proteinuria, initially nephrotic‐range, progressively resolved to subnephrotic by 4 months. At 6 months, the recipient had normalized renal function and sustained resolution of proteinuria. This case demonstrates that removing a kidney from its native pro‐inflammatory environment, coupled with immunosuppression, can facilitate resolution of immune complex‐mediated glomerulopathy.
- 1 January 2026
- Published by Wiley in Case Reports in Transplantation
- Vol. 2026 (1)
Open AccessRethinking Proteinuria: Resolution of Donor Derived EXT2‐Associated Membranous Nephropathy Following Renal Transplantation
Exostosin‐2 (EXT2)‐associated membranous nephropathy (MN) represents a subgroup of immune complex‐mediated renal diseases, where transplantation may facilitate clearance of immune deposits. We present a successful kidney transplantation from a 19‐year‐old deceased donor with previously undiagnosed EXT2‐associated MN into a 75‐year‐old male recipient. Despite significant pretransplant donor proteinuria (> 300 mg/dL) and hypoalbuminemia, renal biopsies at procurement demonstrated well‐preserved renal architecture with minimal interstitial fibrosis. Clinical follow‐up showed improvement in recipient renal function, with serum creatinine decreasing from 3.56 mg/dL preoperatively to 0.96 mg/dL (reference range: 0.7–1.3 mg/dL) within 2 months posttransplant. Proteinuria, initially nephrotic‐range, progressively resolved to subnephrotic by 4 months. At 6 months, the recipient had normalized renal function and sustained resolution of proteinuria. This case demonstrates that removing a kidney from its native pro‐inflammatory environment, coupled with immunosuppression, can facilitate resolution of immune complex‐mediated glomerulopathy.
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- 9 June 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (5) , e70116
Daratumumab for Treatment of Acute Antibody‐Mediated Rejection in a Pediatric Kidney Transplant Recipient
Background: Daratumumab, an anti‐CD38 monoclonal antibody, has shown efficacy as a potential treatment for antibody‐mediated rejection (ABMR) following kidney transplantation in adults. Methods: We present a case demonstrating the use of daratumumab for the management of ABMR in a pediatric kidney transplant recipient. Results: The patient underwent a living‐unrelated donor renal transplant with a post‐transplant course complicated by active ABMR. The patient received a total of four daratumumab infusions with a subsequent decrease in serum creatinine, serum donor‐specific antibody levels, and donor‐derived cell‐free DNA (dd‐cfDNA), which remained low 1 year following treatment. Conclusions: Daratumumab may be a promising treatment consideration for the management of ABMR in pediatric patients following renal transplantation, though further research is needed to better understand its efficacy and side effects. DD‐cfDNA may also be a promising tool to monitor treatment response in conjunction with more traditional methods.
- 1 May 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14535
CMV‐associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient
Background: Cytomegalovirus (CMV) is a significant cause of morbidity among immunocompromised patients who have undergone kidney transplantation and is known to rarely induce collapsing focal segmental glomerulosclerosis (FSGS) among adults.Methods: We present the first reported case of CMV‐induced collapsing FSGS in a pediatric patient after kidney transplant.Results: Our patient underwent a deceased donor kidney transplant due to end‐stage renal disease secondary to lupus nephritis. Approximately 4 months after transplantation, he developed signs of worsening kidney function in the setting of CMV viremia and was found to have collapsing features of FSGS on kidney transplant biopsy. He was managed with a prompt escalation of antiviral therapy along with a reduction of immunosuppression and recovered without significant complication. At follow‐up, he continued to have undetectable CMV titers, creatinine within normal limits, and no significant proteinuria.Conclusion: This report demonstrates CMV as a cause of collapsing FSGS and should be considered among pediatric transplant recipients who present with acute kidney injury, as should early assessment of APOL1 genetic status in both donor and recipient.
- 1 May 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (5) , e14535
CMV‐associated collapsing focal segmental glomerulosclerosis after kidney transplant in a pediatric patient
Background: Cytomegalovirus (CMV) is a significant cause of morbidity among immunocompromised patients who have undergone kidney transplantation and is known to rarely induce collapsing focal segmental glomerulosclerosis (FSGS) among adults.Methods: We present the first reported case of CMV‐induced collapsing FSGS in a pediatric patient after kidney transplant.Results: Our patient underwent a deceased donor kidney transplant due to end‐stage renal disease secondary to lupus nephritis. Approximately 4 months after transplantation, he developed signs of worsening kidney function in the setting of CMV viremia and was found to have collapsing features of FSGS on kidney transplant biopsy. He was managed with a prompt escalation of antiviral therapy along with a reduction of immunosuppression and recovered without significant complication. At follow‐up, he continued to have undetectable CMV titers, creatinine within normal limits, and no significant proteinuria.Conclusion: This report demonstrates CMV as a cause of collapsing FSGS and should be considered among pediatric transplant recipients who present with acute kidney injury, as should early assessment of APOL1 genetic status in both donor and recipient.
- 1 September 2002
- Published by Wiley in Pediatric Transplantation
- Vol. 6 (4) , 352-355
Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor‐free immunosuppression regimen
Recurrence of hemolytic uremic syndrome (HUS) after kidney transplantation is frequent, occurring almost exclusively in patients with atypical HUS, which is not caused by Escherichia coli gastroenteritis and in which diarrhea is absent. Calcineurin inhibitors are associated with recurrence of HUS. In two children who underwent living donor kidney transplantation for atypical HUS, we pre‐emptively employed sirolimus in a calcineurin inhibitor‐free immunosuppression regimen. Both children had excellent early graft function, yet both developed severe recurrent disease and subsequently lost their grafts. Avoidance of calcineurin inhibitors did not prevent recurrence of severe HUS and graft loss. Transplantation for severe atypical HUS remains problematic.
- 1 September 2002
- Published by Wiley in Pediatric Transplantation
- Vol. 6 (4) , 352-355
Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor‐free immunosuppression regimen
Recurrence of hemolytic uremic syndrome (HUS) after kidney transplantation is frequent, occurring almost exclusively in patients with atypical HUS, which is not caused by Escherichia coli gastroenteritis and in which diarrhea is absent. Calcineurin inhibitors are associated with recurrence of HUS. In two children who underwent living donor kidney transplantation for atypical HUS, we pre‐emptively employed sirolimus in a calcineurin inhibitor‐free immunosuppression regimen. Both children had excellent early graft function, yet both developed severe recurrent disease and subsequently lost their grafts. Avoidance of calcineurin inhibitors did not prevent recurrence of severe HUS and graft loss. Transplantation for severe atypical HUS remains problematic.